Alcami recently contributed to an eBook produced by Drug Development and Delivery. The eBook, titled "Analytical Testing in Drug Development," features four companies and explains how they each help the pharmaceutical and biotech industries comply with drug development regulatory requirements.
Angela Moore, abuse-deterrence studies subject matter expert at Alcami, contributed to the eBook. Her article focuses on considerations for abuse-deterrent Category 1 studies as well as standard syringeability studies.
"Healthcare professionals around the world are commonly prescribing opioid medications for pain management, generating an inevitable association with abuse and addiction. The Centers for Disease Control and Prevention (CDC) has estimated that, in 2017, over 47,600 Americans died from opioid overdoses. Of these deaths, 35% involved the use of prescription opioid medications."
MORE CONTENT RELATED TO ABUSE-DETERRENT STUDIES
- ON-DEMAND WEBINAR: Abuse-Deterrent Category One Testing: Syringeability Studies
- Editorial: Overcoming the Opioid Overdose Crisis
- Abuse-Deterrent Studies – An Interview with Angela Moore
- Executive Brief: An Opioid Abuse-Deterrent Roadmap for the Pharmaceutical Industry
Ready to Get Started?
